CCM
IDIX

Camber Capital Management’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Camber Capital Management’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,750,000
Closed -$9.93M – 47
2013
Q2 		$9.93M Buy
+2,750,000
New +$11.2M 1.02% 27

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Camber Capital Management's IDIX Position: Q3 2013 in Review

Camber Capital Management sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2013, closing a stake of 2,750,000 shares — an estimated $9.93M sold.

Camber Capital Management first reported a position in IDIX in Q2 2013 and held it in 1 quarter. The position peaked at $9.93M in Q2 2013. 93 funds tracked by Wall St. Rank hold IDIX as of Q3 2013.

  • Camber Capital Management reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Camber Capital Management sold 2,750,000 IDENIX PHARMACEUTICALS INC shares in Q3 2013, an estimated $9.93M.
  • Camber Capital Management first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Camber Capital Management's IDENIX PHARMACEUTICALS INC position peaked at $9.93M in Q2 2013.
  • 93 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2013.

Based on Camber Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.